Edition:
India

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

139.51USD
19 Jan 2018
Change (% chg)

-- (--)
Prev Close
$139.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
187,057
52-wk High
$169.58
52-wk Low
$112.15

Chart for

About

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH):... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $5,381.27
Shares Outstanding(Mil.): 43.44
Dividend: --
Yield (%): --

Financials

BRIEF-Corsair Pharma And United Therapeutics Enter Into Strategic Collaboration To Advance Novel Treprostinil Prodrugs

* CORSAIR PHARMA AND UNITED THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE NOVEL TREPROSTINIL PRODRUGS

03 Jan 2018

United Therapeutics to pay $210 million to resolve U.S. kickback probe

BOSTON United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

20 Dec 2017

United Therapeutics to pay $210 million to resolve U.S. kickback probe

BOSTON United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

20 Dec 2017

UPDATE 2-United Therapeutics to pay $210 mln to resolve U.S. kickback probe

BOSTON, Dec 20 United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

20 Dec 2017

United Therapeutics to pay $210 mln to resolve U.S. kickback probe

BOSTON, Dec 20 United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

20 Dec 2017

BRIEF-STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT

* ‍COURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8,497,393 OWNED BY UNITED THERAPEUTICS​

14 Nov 2017

BRIEF-United Therapeutics Corp reports third quarter 2017 financial results

* United Therapeutics Corporation reports third quarter 2017 financial results

25 Oct 2017

BRIEF-United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system

* United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system

23 Oct 2017

BRIEF-United Therapeutics Corp reports Q2 EPS non-GAAP $4.37

* United Therapeutics Corporation reports second quarter 2017 financial results

27 Jul 2017

Earnings vs. Estimates